Thermo Fisher (NYSE: TMO) CEO trades 4,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 4,000 shares of common stock and reported related trades in Thermo Fisher Scientific Inc. stock. The option exercise, at an exercise price of $0.00 per share, converted into 4,000 shares of common stock.

On the same date, he sold 4,000 shares of common stock in a series of open-market transactions at prices ranging from $503.66 to $519.74, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 125,360.358 shares of common stock.

Additional shares are held indirectly by the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares) and the MNC 2020 Irrevocable Trust (5,000 shares, all as of the reported date), with Casper disclaiming beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASPER MARC N

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		M		4,000	A	$309.63	127,925.358	D
Common Stock	03/05/2026		S(1)		20	D	$503.66	127,905.358	D
Common Stock	03/05/2026		S(1)		60	D	$505.76(2)	127,845.358	D
Common Stock	03/05/2026		S(1)		58	D	$507.54(3)	127,787.358	D
Common Stock	03/05/2026		S(1)		99	D	$509.66(4)	127,688.358	D
Common Stock	03/05/2026		S(1)		214	D	$511.78(5)	127,474.358	D
Common Stock	03/05/2026		S(1)		411	D	$512.73(6)	127,063.358	D
Common Stock	03/05/2026		S(1)		1,133	D	$513.71(7)	125,930.358	D
Common Stock	03/05/2026		S(1)		570	D	$514.71(8)	125,360.358	D
Common Stock	03/05/2026		S(1)		348	D	$515.64(9)	125,012.358	D
Common Stock	03/05/2026		S(1)		201	D	$516.73(10)	124,811.358	D
Common Stock	03/05/2026		S(1)		106	D	$517.83(11)	124,705.358	D
Common Stock	03/05/2026		S(1)		516	D	$519.13(12)	124,189.358	D
Common Stock	03/05/2026		S(1)		264	D	$519.74(13)	123,925.358	D
Common Stock								11,300	I	By Alison Casper 2020 Irrevocable Trust(14)
Common Stock								14,608	I	By Floral Park Associates, Inc.
Common Stock								5,000	I	By MNC 2020 Irrevocable Trust(15)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$309.63	03/05/2026		M			4,000	(16)	02/25/2027	Common Stock	4,000	$0	40,550	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.36 to $506.16, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.40 to $508.12, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.63 to $509.76, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.21 to $512.18, inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.23 to $513.22, inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.27 to $514.24, inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.24, inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.30 to $516.00, inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.47 to $517.07, inclusive.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.60 to $518.16, inclusive.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.62 to $519.57, inclusive.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.62 to $519.91, inclusive.

14. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.

15. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.

16. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.

	/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Thermo Fisher (TMO) CEO Marc N. Casper report in this Form 4 filing?

Marc N. Casper reported exercising stock options for 4,000 shares and related trades in Thermo Fisher common stock. He then sold 4,000 shares in multiple open-market transactions, while remaining a significant direct and indirect holder of Thermo Fisher shares.

How many Thermo Fisher (TMO) shares did the CEO sell and at what prices?

Marc N. Casper sold 4,000 shares of Thermo Fisher common stock in several open-market trades. The reported sale prices ranged from about $503.66 to $519.74 per share, based on weighted-average prices disclosed for each transaction block.

Did Thermo Fisher (TMO) CEO Marc N. Casper use a 10b5-1 plan for these trades?

Yes. The filing states all reported transactions were made under a Rule 10b5-1 trading plan adopted by Marc N. Casper on November 11, 2025. Such plans pre-schedule trades, helping separate personal trading decisions from nonpublic company information.

How many Thermo Fisher (TMO) shares does Marc N. Casper own directly after these transactions?

After the reported option exercise and share sales, Marc N. Casper directly held 125,360.358 shares of Thermo Fisher common stock. This figure reflects his direct ownership position as of the transaction date disclosed in the Form 4 filing.

What indirect Thermo Fisher (TMO) holdings are associated with Marc N. Casper?

Indirect holdings include 11,300 shares held by the Alison Casper 2020 Irrevocable Trust, 14,608 shares held by Floral Park Associates, Inc., and 5,000 shares held by the MNC 2020 Irrevocable Trust. The reporting person disclaims beneficial ownership except for any pecuniary interest.

What kind of derivative security did the Thermo Fisher (TMO) CEO exercise?

He exercised a stock option (right to buy) covering 4,000 shares of Thermo Fisher common stock at an exercise price of $0.00 per share. The option had vested in four equal installments in 2021, 2022, 2023 and 2024.